MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
convertible notes payable
$988,472
Proceeds from issuance of
series d preferred...
$192,338
Proceeds from issuance of
pre-delivery shares
$4,750
Net cash provided by
financing activities
$1,161,698
Canceled cashflow
$23,862
Decrease in cash and cash
equivalents
-$758,022
Canceled cashflow
$1,161,698
Stock based
compensation
$516,180
Accounts payable
$496,242
Accrued liabilities
$419,263
Loss on issuance of
convertible note
-$280,764
Amortization of debt discount
$115,184
Prepaid expenses and
other assets
-$77,705
Depreciation and
amortization
$63,257
Interest payable
$41,023
Amortization of license fees
$22,500
Deferred offering costs
$23,862
Net cash used in
operating activities
-$1,919,720
Canceled cashflow
$2,032,118
Net loss
-$3,738,821
Inventory
$69,052
Accounts receivable
$64,682
Deferred revenue
-$63,765
Amortization of right-of-use
assets, net of...
$7,781
Change in fair value of
derivative liability
-$7,737
Back
Back
Cash Flow
source: myfinsight.com
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)